Vimta Labs

Vimta Labs EBITDA per Share

The EBITDA per Share of Vimta Labs (VIMTALABS.NS) as of Oct 27, 2026 is 21.99 INR. In the previous year, EBITDA per Share was 28.01 INR — a change of -21.48% (lower).

EBITDA per Share

21.99INR

YoY

-21.48%

Last updated:

EBITDA per Share of Vimta Labs is 2026 21.99 INR. EBITDA per Share of Vimta Labs was 2025 28.01 INR. It decreases by -21.48% lower compared to the previous year.

The Vimta Labs EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
29.56 INR
Jan 1, 2020
15.65 INR
Jan 1, 2021
26.18 INR
Jan 1, 2022
35.35 INR
Jan 1, 2023
44.59 INR
Jan 1, 2024
43.21 INR
Jan 1, 2025
28.01 INR
Jan 1, 2026
21.99 INR
The Vimta Labs EBITDA per Share history
YEAREBITDA per ShareYoY
21.99INR-21.48%
28.01INR-35.19%
43.21INR-3.08%
44.59INR+26.13%
35.35INR+35.03%
26.18INR+67.31%
15.65INR-47.07%
29.56INR+32.72%
22.27INR+69.25%
13.16INR+44.99%
9.08INR+0.65%
9.02INR-25.08%
12.04INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vimta Labs Stock analysis

What does Vimta Labs do? Vimta Labs Ltd. provides contract research and testing services across multiple industries including biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, power, cement, oil and gas, ores and minerals, and infrastructure. The company serves biopharmaceutical firms, medical device companies, agrochemical and specialty chemical firms, food manufacturers, processors, farmers, retailers, hospitals, and government organizations. Its services include drug discovery, development, and life cycle management support; preclinical research for medical devices; contract research for agrochemical and specialty chemicals; food testing and analytical development; clinical diagnostics for patients and hospitals; and environmental regulatory services like impact assessments and post-project monitoring for power and infrastructure sectors. The primary buyers of Vimta Labs' services are biopharmaceutical companies requiring drug development support, medical device manufacturers needing preclinical testing, agrochemical firms seeking contract research, food industry stakeholders such as manufacturers and retailers, healthcare providers including hospitals, and government entities requiring environmental assessments. These segments represent the core revenue streams for the company through its specialized testing and research offerings. Vimta Labs generates revenue by delivering tailored research and testing solutions to industry-specific clients across diverse sectors. The company’s service portfolio targets key industries where regulatory compliance and product safety are critical, ensuring consistent demand for its analytical and diagnostic services. By maintaining a broad service range, Vimta Labs secures contracts with multiple industry participants, including government organizations, to sustain its business model. Vimta Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vimta Labs stock

EBITDA per Share of Vimta Labs is 21.99 INR in 2026.

EBITDA per Share of Vimta Labs changed from 28.01 INR to 21.99 INR, representing a -21.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Vimta Labs since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Vimta Labs

All Key Metrics — Vimta Labs